Alpine Immune Sciences (NASDAQ:ALPN) Stock Price Crosses Above 200 Day Moving Average of $7.37

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $7.37 and traded as high as $8.09. Alpine Immune Sciences shares last traded at $8.05, with a volume of 44,222 shares traded.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ALPN shares. Wedbush lifted their target price on Alpine Immune Sciences to $25.00 in a report on Thursday, September 15th. SVB Leerink started coverage on Alpine Immune Sciences in a report on Monday, November 21st. They issued an “outperform” rating and a $15.00 target price on the stock. Oppenheimer decreased their target price on Alpine Immune Sciences from $17.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, October 24th. Finally, HC Wainwright decreased their target price on Alpine Immune Sciences from $21.00 to $8.00 in a report on Monday, October 24th.

Alpine Immune Sciences Price Performance

The firm has a market cap of $244.73 million, a PE ratio of -4.50 and a beta of 1.29. The business has a fifty day moving average price of $6.59 and a two-hundred day moving average price of $7.37.

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.32). Alpine Immune Sciences had a negative net margin of 169.92% and a negative return on equity of 41.76%. The business had revenue of $8.37 million for the quarter, compared to analysts’ expectations of $20.43 million. As a group, sell-side analysts forecast that Alpine Immune Sciences, Inc. will post -1.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its position in Alpine Immune Sciences by 10.1% during the third quarter. Bank of New York Mellon Corp now owns 64,480 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 5,926 shares during the last quarter. BNP Paribas Arbitrage SNC boosted its position in Alpine Immune Sciences by 88.7% during the third quarter. BNP Paribas Arbitrage SNC now owns 6,572 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 3,090 shares during the last quarter. State Street Corp boosted its position in Alpine Immune Sciences by 4.1% during the third quarter. State Street Corp now owns 278,982 shares of the biotechnology company’s stock valued at $2,009,000 after purchasing an additional 10,900 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Alpine Immune Sciences during the third quarter valued at $35,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Alpine Immune Sciences during the third quarter valued at $128,000.

Alpine Immune Sciences Company Profile

(Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.